IMR Press / FBL / Volume 17 / Issue 5 / DOI: 10.2741/4018

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
RHAMM and CD44 peptides-analytic tools and potential drugs
Show Less
1 London Regional Cancer Center, University of Western Ontario, London, ON, Canada N6A 4L6
2 The Lautenberg Center for General and Tumor Immunology, Hebrew University–Hadassah Medical School, Jerusalem 91120, Israel

Academic Editor: Darja Kanduc

Front. Biosci. (Landmark Ed) 2012, 17(5), 1775–1794;
Published: 1 January 2012
(This article belongs to the Special Issue Peptides: from basic research to clinical applications)

CD44 and RHAMM are two extracellar matrix receptors whose principle ligand is the polysaccharide hyaluronan (HA). Both proteins are involved in wound repair and their aberrant regulation contributes to a variety of diseases including arthritis and cancer. Over the past decade, a number of peptide-based therapeutics that block the binding of CD44 or RHAMM-specific ligands have been developed and tested in experimental models of disease. Here, we review the structure of each of these proteins, the functions they control and the mechanisms, including their interactions with each other, responsible for these functions. We also review the development of peptide mimics that block the key functions of CD44 and RHAMM and their use in experimental models of disease.

Back to top